BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37531591)

  • 1.
    Äärelä A; Auchynnikava T; Moisio O; Liljenbäck H; Andriana P; Iqbal I; Lehtimäki J; Rajander J; Salo H; Roivainen A; Airaksinen AJ; Virta P
    Mol Pharm; 2023 Oct; 20(10):5043-5051. PubMed ID: 37531591
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative evaluation of the improvement in the pharmacokinetics of a nucleic acid drug delivery system by dynamic PET imaging with (18)F-incorporated oligodeoxynucleotides.
    Mukai H; Ozaki D; Cui Y; Kuboyama T; Yamato-Nagata H; Onoe K; Takahashi M; Wada Y; Imanishi T; Kodama T; Obika S; Suzuki M; Doi H; Watanabe Y
    J Control Release; 2014 Apr; 180():92-9. PubMed ID: 24566256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of
    Ren Q; Mohri K; Warashina S; Wada Y; Watanabe Y; Mukai H
    Mol Pharm; 2019 Mar; 16(3):1065-1073. PubMed ID: 30633529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging of a
    Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
    Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules.
    Cheng Z; De Jesus OP; Namavari M; De A; Levi J; Webster JM; Zhang R; Lee B; Syud FA; Gambhir SS
    J Nucl Med; 2008 May; 49(5):804-13. PubMed ID: 18413392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer.
    Chen L; Fu H; He H; Lou K; Li Q; Ye J; Feng G; Yu C
    Mol Pharm; 2023 Aug; 20(8):4277-4284. PubMed ID: 37463487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro and In Vivo Characterization of
    Allen KJH; Jiao R; Li J; Beckford-Vera DR; Dadachova E
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235126
    [No Abstract]   [Full Text] [Related]  

  • 10. Positron emission tomography (PET) guided glioblastoma targeting by a fullerene-based nanoplatform with fast renal clearance.
    Peng Y; Yang D; Lu W; Hu X; Hong H; Cai T
    Acta Biomater; 2017 Oct; 61():193-203. PubMed ID: 28801268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma Imaging Using
    Zhang C; Zhang Z; Lin KS; Lau J; Zeisler J; Colpo N; Perrin DM; Bénard F
    Mol Pharm; 2018 Jun; 15(6):2116-2122. PubMed ID: 29714486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of Site-Specific Antibody-[60]Fullerene-Oligonucleotide Conjugates for Cellular Targeting.
    Äärelä A; Räsänen K; Holm P; Salo H; Virta P
    ACS Appl Bio Mater; 2023 Aug; 6(8):3189-3198. PubMed ID: 37432881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Evaluation of
    Zhou L; Long R; Hu M; Liu N; Feng Y; Qiu L; Li Z; Chen Y; Wang L
    Mol Pharm; 2022 Jul; 19(7):2191-2202. PubMed ID: 35473312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor.
    Miao Z; Ren G; Jiang L; Liu H; Webster JM; Zhang R; Namavari M; Gambhir SS; Syud F; Cheng Z
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1977-84. PubMed ID: 21761266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
    Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of [
    Li X; Hu K; Liu W; Wei Y; Sha R; Long Y; Han Y; Sun P; Wu H; Li G; Tang G; Huang S
    Nucl Med Biol; 2020; 90-91():84-92. PubMed ID: 33189948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiofluorinated probe for PET imaging of fatty acid binding protein 4 in cancer.
    Temma T; Nishigori K; Onoe S; Sampei S; Kimura I; Ono M; Saji H
    Nucl Med Biol; 2015 Feb; 42(2):184-91. PubMed ID: 25457456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.